Shilpa Medicare Reports Strong Financial Performance in Q3 2024

Shilpa Medicare, a midcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company has shown a very positive performance in this quarter, with a score of 28, which is an improvement from 19 in the last 3 months.

According to the financials, Shilpa Medicare has seen a significant growth in its Profit Before Tax (PBT) and Profit After Tax (PAT) for the quarter. PBT has grown by 119.5% to Rs 31.78 crore, while PAT has grown by 82.5% to Rs 17.94 crore, compared to the average of the previous four quarters. This trend is expected to continue in the near future.

The company's ability to manage interest payments has also improved, with the Operating Profit to Interest ratio being the highest in the last five quarters. The Operating Profit (PBDIT) has also shown a positive trend, with each quarter in the last five quarters showing growth. The Inventory Turnover Ratio has also been the highest in the last five half yearly periods, indicating that the company has been able to sell its inventory faster.

However, the company's short term liquidity has deteriorated, with the Cash and Cash Equivalents being the lowest in the last six half yearly periods. The Dividend Payout Ratio (DPR) has also been the lowest in the last five years, indicating that the company is distributing a lower proportion of its profits as dividends.

Overall, Shilpa Medicare has shown a strong financial performance in the quarter ending September 2024, with positive trends in key areas such as PBT, PAT, and Operating Profit. Investors are advised to hold their stocks, as recommended by MarketsMOJO.